BioSpace News Archive

Deals

RXi Pharmaceuticals Announces Pricing Of $15 Million Upsized Underwritten Public Offering

RXi Pharmaceuticals Corporation today announced the pricing of an underwritten public offering of 21,428,572 units at a price to the public of $0.70 per unit.

October 1, 2018
·
5 min read
Targovax Presented ONCOS-102 Poster at 13th International Adenovirus Meeting

Targovax ASA announces that the Company presented at the following conference:

October 1, 2018
·
1 min read
Drug Development

Seattle Genetics and Takeda Announce Positive Results from Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline CD30-Expressing Peripheral T-Cell Lymphoma

ADCETRIS in Combination with Chemotherapy Achieved Primary Endpoint, Demonstrating a Statistically Significant Improvement in Progression-Free Survival Compared to a Standard of Care Chemotherapy

October 1, 2018
·
25 min read
Pharm Country

Lannett Launches Five New Products In Fiscal 2019 First Quarter

Lannett Company, Inc. today announced that it commenced marketing five new products in its recently completed fiscal 2019 first quarter, bringing to 12 the total number of products launched since January 1, 2018.

October 1, 2018
·
2 min read
Bio NC

TransEnterix Receives CE Mark Approval for Senhance Ultrasonic Instrument System

Receives CE Mark for Senhance™ Ultrasonic, Advanced Energy Capability Broadens the Potential Applicability of Senhance Surgery in CE Mark Countries

October 1, 2018
·
3 min read
Business

MD Anderson immunologist Jim Allison awarded Nobel Prize

T cell discoveries led to game-changing treatment revolutionizing cancer care

October 1, 2018
·
5 min read
Business

Bruker Announces Breakthrough Proteomics and Lipidomics Workflow Advances for the timsTOF™ Pro at HUPO 2018

First Large-Scale Use of Peptide CCS Values to Enhance Search Specificity

October 1, 2018
·
8 min read
Pharm Country

The Breast Cancer Research Foundation Marks 25 Years of Impact with Record-Breaking $63 Million Investment in Cancer Research Worldwide

BCRF announces priority research areas for 2018-2019

October 1, 2018
·
5 min read
Drug Development

The Medicines Company Announces Recommendation by Independent Data Monitoring Committee to Continue Inclisiran Phase III Trials Following Fourth Review of Unblinded Data

More than 1,899 patient-years of safety data accumulated to date – a five-fold increase over total patient exposure through Phase II trials

October 1, 2018
·
4 min read
Business

Appili Therapeutics Appoints Veteran Drug Development Executive, Dr. Armand Balboni, as Its Inaugural Chief Scientific Officer

Appili Therapeutics Inc. has named Dr. Armand Balboni as its first Chief Scientific Officer (CSO).

October 1, 2018
·
4 min read